TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36194074
Drug: Smartphone app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors, used daily over 1 month.
Study: 36194074
Drug: Smartphone app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors, used daily over 1 month (adherent subgroup).
Study: 35254390
Drug: Intensive vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vs Standard Treatment
Study: 35254390
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment in participants with history of cardiovascular disease
Study: 39439530
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone
Study: 35543942
Drug: Oral motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral motor therapy alone
Study: 36263703
Drug: Propolis supplementation
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis supplementation (510 mg per day)
Study: 35849886
Drug: Nurse-led medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led medication self-management intervention
Study: 36233538
Drug: Hochuekkito (TJ‐41)
Normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hochuekkito (TJ‐41) treatment combined with pulmonary rehabilitation (PR) for 12 weeks
Study: 32063619
Drug: Letrozole 5mg
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 5mg tablets per night for 3-7 days
Study: 32063619
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50mg tablets per night for 3-7 days
Study: 33345452
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (assumed risk reduction based on EMPA-REG OUTCOME and DECLARE-TIMI 58 trials)
Study: 35939559
Drug: ESO 40
Normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO 40 mg Bid plus AMX 1 g Tid for 14 days (Group B)
Study: 35939559
Drug: ESO 20
Normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO 20 mg plus AMX 1 g, Tid for 14 days (Group C)
Study: 38770818
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors
Study: 36167363
Drug: Low-dose high-intensity
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose high-intensity training (1×4 min intervals at ~90% of maximal heart rate and 2×4 repetitions strength training at ~90% of 1 repetition maximum)
Study: 34596367
Drug: Anlotinib 12
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg/day
Study: 35456220
Drug: Intragastric botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric botulinum toxin A (BT‐A) injection
Study: 37680791
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol
Study: 37878624
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF
Study: 36821841
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin
Study: 32880220
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (0.45 mg/day) with progesterone (200 mg/day for 12 days/month)
Study: 32503359
Drug: Thoracic intraarticular
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic intraarticular facet joint injections
Study: 34347093
Drug: TransCon PTH
Normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon PTH 15, 18, or 21 µg PTH(1‐34)/day
Study: 32033579
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antipsychotic medication until at least 1 year after remission (original dose allowing a maximum reduction of 25%, or another antipsychotic drug in similar dose range)
Study: 32634673
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonists (GnRHa)
Study: 34538193
Drug: Traditional occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional occupational therapy (TOT)
Study: 38108919
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonists (VKAs)
Study: 32925778
Drug: modified Ban-Xia-Xie-Xin-Decotion
Normalized name: Xia ye fan xie
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Ban-Xia-Xie-Xin-Decotion plus basic treatment
Study: 38359528
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy
Study: 35749631
Drug: Oxaliplatin treatment
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin treatment
Study: 36562843
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride + chondroitin sulfate (G + C)
Study: 34058654
Drug: Early onset
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early onset (EO) patients with early non-improvement after 2 weeks of therapy (<20% improvement)
Study: 32529637
Drug: Other medical
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medical therapy
Study: 32271718
Drug: Exebacase +
Normalized name: Exebacase
DrugBank: Exebacase (DB16161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exebacase + antibiotics (MRSA subgroup)
Study: 38175642
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin
Study: 34823018
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin
Study: 38670610
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone
Study: 34098984
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm (dihydroartemisinin-piperaquine) vs Control arm (screening and treatment).
Study: 36138465
Drug: UFNET rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UFNET rate set on the CRRT of at least 100 ml h‐1 between inclusion and H72 of inclusion if hemodynamically tolerated based on a protocolized hemodynamic protocol.
Study: 35862082
Drug: Empagliflozin-ramipril combination
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empagliflozin-ramipril combination treatment
Study: 35305913
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 800 mg infusion
Study: 32125256
Drug: Paclitaxel drug-coated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-coated balloon (DCB) angioplasty
Study: 32721210
Drug: Immediate Bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate Bronchial Thermoplasty (BT) treatment (n=20)
Study: 32109194
Drug: Concurrent rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent rituximab (375 mg/m2) with cladribine (0.15 mg/kg)
Study: 39626074
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline
Study: 34510814
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (degarelix)
Study: 33030881
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol alone (100 micrograms)
Study: 32408905
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by endocrine therapy
Study: 32419678
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine infusion (0.2 mg/kg and 0.5 mg/kg)
Study: 33001851
Drug: Nurse-led intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led intervention on video-assisted teaching regarding nature of the disease condition including diet, medication, hand and leg exercises, home care management for 30 mins.
Study: 33429768
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg/d for 10 days, 20 days free of treatment, repeated for 3 courses over 3 months
Study: 36235736
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 3 × 400 mg per day for 4 weeks
Study: 33663235
Drug: Empagliflozin add-on
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin add-on therapy
Study: 39028879
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA)
Study: 36069869
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump (control)
Study: 32655129
Drug: HDAC3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HDAC3 treatment in GC cells
Study: 33560478
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy
Study: 39560745
Drug: CC
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC
Study: 36096203
Drug: Remibrutinib 10
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remibrutinib 10 mg twice daily
Study: 36096203
Drug: Remibrutinib 25
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remibrutinib 25 mg twice daily
Study: 36096203
Drug: Remibrutinib 100
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remibrutinib 100 mg twice daily
Study: 32814667
Drug: Step-up oral
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up oral food challenge testing (SOFT)
Study: 33233972
Drug: Computerised word
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised word finding therapy plus usual care
Study: 35844443
Drug: Nursing interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing interventions including health education, psychological intervention, medication guidance, complication prevention, and follow-up management
Study: 33894131
Drug: suvratoxumab 5000
Normalized name: Suvratoxumab
DrugBank: Suvratoxumab (DB15172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvratoxumab 5000 mg
Study: 35429465
Drug: 6-month oral
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month oral itraconazole
Study: 35947082
Drug: 3.6 ml
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 ml 2% mepivacaine hydrochloride with 1:100,000 adrenalin
Study: 35103951
Drug: Faster insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster insulin aspart (FIA)
Study: 39294797
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection
Study: 33036537
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) for 30 minutes once daily for 30 days
Study: 37303683
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel
Study: 35291272
Drug: Sugarcane bagasse
Normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugarcane bagasse at doses of 5, 10, and 15 g/d
Study: 34133809
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (without VR) during painful dental procedures requiring local anesthesia
Study: 36521773
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment only (Control)
Study: 32482112
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human parathyroid hormone (20 μg/day, n=35)
Study: 32608001
Drug: Selenomethionine (SM)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (SM) at 0.4 mg/kg diet (SM2)
Study: 32608001
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (SS) at 0.2 mg/kg diet (SS1)
Study: 39527055
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment
Study: 32176112
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1g in 100mL saline solution applied for 5 minutes before wound closure
Study: 33142537
Drug: 20 and
Normalized name: zinc pyrithione 20 MG/ML [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 and 30 mg/kg Mn
Study: 34300291
Drug: General post-surgical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General post-surgical treatment protocol
Study: 32967864
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy
Study: 34870584
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Study: 32027157
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) protocols for anxiety disorders
Study: 34291796
Drug: Triple Antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple Antibiotic Solution (TAS)
Study: 33459698
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy with 35 mm cup
Study: 32703001
Drug: Mirror book
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirror book therapy in conjunction with standard facial rehabilitation
Study: 36400384
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (nCT)
Study: 34049452
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis (5 mg THC)
Study: 33677832
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy
Study: 39716202
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group
Study: 34649553
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education intervention (OHE) given at baseline, third and sixth months
Study: 35934778
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg pitavastatin
Study: 32862676
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) - two doses of maximum 1 g each
Study: 33439085
Drug: Specialised oral
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised oral nutritional supplement (ONS) containing arginine and proline, high in vitamins A, C, E, zinc, and selenium, 200ml twice daily for four weeks.
Study: 34033447
Drug: Premature infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature infant oral motor intervention (PIOMI)
Study: 32080862
Drug: Treprostinil iontophoresis
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treprostinil iontophoresis (1 mg/mL hydrogel)
Study: 32439008
Drug: Selatogrel 16
Normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel 16 mg
Study: 32501914
Drug: Intravenous EACA
Normalized name: EACA
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous EACA
Study: 33475138
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (CONT)
Study: 39124613
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment)
Study: 32448804
Drug: Camrelizumab combined
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab combined with apatinib (continuous dosing)
Study: 38713248
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC)
Study: 38755699
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups
Study: 35575012
Drug: Weekly patient-reported
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly patient-reported outcome—common terminology criteria for adverse event assessments
Study: 33310419
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone tapering (OPT)
Study: 35353088
Drug: Alveolar ridge
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alveolar ridge preservation technique with implant placement 4 months later
Study: 33785743
Drug: Peginterferon Lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon Lambda-1a (180 mcg subcutaneous dose)
Study: 36940437
Drug: 14-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day hybrid therapy
Study: 34215501
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone
Study: 32511774
Drug: Liberalized dietary
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberalized dietary sodium intake (200 mmol/d, 4600 mg/d)
Study: 36342337
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention about health, medication use, and communication strategies
Study: 33226425
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d ezogabine
Study: 37813304
Drug: Continuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous oxytocin infusion
Study: 37882059
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT)
Study: 32133487
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline 100 mg twice daily for 4 weeks
Study: 39247971
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT)
Study: 39315334
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine